Difference between revisions of "Template:Current week ecosystem agenda"
From Bioblast
Tindle Lisa (talk | contribs) |
|||
| Line 1: | Line 1: | ||
2020 Week 27 | |||
* '''Jun- | * '''Jun-29 Mo''' | ||
:{| | :{| | ||
| width="110" align="center" | [[Image:O2k-Support.jpg|60px|link=http://wiki.oroboros.at/index.php/O2k-Open_Support |O2k-Open Support]][[File: | | width="110" align="center" | [[Image:O2k-Support.jpg|60px|link=http://wiki.oroboros.at/index.php/O2k-Open_Support |O2k-Open Support]][[File:Red-loss of data.png|25px|Warning: loss of data]] | ||
| ''' | |'''How to decide whether the noise of the O2 slope neg. is within recommended values?'''<br> | ||
- » [[Oxygen_calibration_-_DatLab#Instrumental_DL-Protocols| Noise of 'O2 slope neg.']]« | |||
- »[[ | |||
|} | |} | ||
---- | ---- | ||
* '''Jun- | * '''Jun-30 Tu''' | ||
:{| | :{| | ||
| width="100" align="center" |[[Image:O2k-Publications.jpg|70px|link=http://wiki.oroboros.at/index.php/O2k-Publications:_Topics |O2k-Publications in the MiPMap]] | | width="100" align="center" |[[Image:O2k-Publications.jpg|70px|link=http://wiki.oroboros.at/index.php/O2k-Publications:_Topics |O2k-Publications in the MiPMap]] | ||
|''' | |'''The antidiabetic drug empagliflozin protects cardiac mitochondria against high-fat diet-induced dysfunction in mice'''<br> | ||
:from the O2k-Network »[[ | :from the O2k-Network »[[LV Riga Makrecka-Kuka M]]« | ||
* | *Makrecka-Kuka M, Korzh S, Videja M, Vilks K, Cirule H, Kuka J, Dambrova M, Liepinsh E (2020) Empagliflozin protects cardiac mitochondrial fatty acid metabolism in a mouse model of diet-induced lipid overload. Cardiovasc Drugs Ther [Epub ahead of print]. [[Makrecka-Kuka 2020 Cardiovasc Drugs Ther|»Bioblast link«]] | ||
|} | |} | ||
---- | ---- | ||
* ''' | * '''Jul-01 We''' | ||
---- | ---- | ||
* ''' | * '''Jul-02 Th''' | ||
:{| | :{| | ||
| width="110" align="center" | [[File:MitoPedia.jpg|left|80px|MitoPedia]] | | width="110" align="center" | [[File:MitoPedia.jpg|left|80px|MitoPedia]] | ||
| '''Did you know that | | '''Did you know that if [[ET_capacity|ET capacity]] [[File:E.jpg]] is lower than [[OXPHOS_capacity|OXPHOS capacity]] [[File:P.jpg]] ([[ET_capacity#The_important_difference_between_states_P_and_E|''P''>''E'']]) in [[Living_cells | living cells]] or [[Mitochondrial_preparations | mitochondrial preparations]], then you have encountered an experimental artefact? The possible triggers of this experimental artefact are:''' <br> | ||
- | - loss of oxidative capacity during the time course of the respirometric assay,<br> | ||
- insufficient [[Uncoupler|uncoupler]] concentrations,<br> | |||
- over titration of an uncoupler, which inhibits ET capacity,<br> | |||
- inhibition of ET capacity due to the use of high [[Oligomycin|oligomycin]] (inhibitor of the ATP synthase) concentrations employed to measure [[LEAK_respiration|LEAK respiration]] prior ET capacity. | |||
Information from: Gnaiger Erich ''et al'' ― MitoEAGLE Task Group (2020) Mitochondrial physiology. Bioenerg Commun 2020.1 »[[BEC_2020.1_doi10.26124bec2020-0001.v1|Bioblast link]]« | |||
|} | |} | ||
---- | ---- | ||
* ''' | * '''Jul-03 Fr''' | ||
:{| | |||
{| | | width="100" align="center" | [[File:O2k-brief.png|45px|link=http://wiki.oroboros.at/index.php/O2k-brief|O2k-brief repository]] | ||
|'''Mitochondrial H<sub>2</sub>O<sub>2</sub> flux in cardiac and skeletal muscle preparations is influenced by experimental oxygen concentration''' <br> | |||
: from the O2k-Network »[[US CO Fort Collins Chicco AJ]]« <br> | |||
[[ | * Li Puma LC, Hedges M, Heckman JM, Mathias AB, Engstrom MR, Brown AB, Chicco AJ (2020) Experimental oxygen concentration influences rates of mitochondrial hydrogen peroxide release from cardiac and skeletal muscle preparations. Am J Physiol Regul Integr Comp Physiol 318:R972-80. [[Li Puma 2020 Am J Physiol Regul Integr Comp Physiol|»Bioblast link«]] | ||
|} | |} | ||
Revision as of 08:08, 29 June 2020
2020 Week 27
- Jun-29 Mo
How to decide whether the noise of the O2 slope neg. is within recommended values?
- Jun-30 Tu
The antidiabetic drug empagliflozin protects cardiac mitochondria against high-fat diet-induced dysfunction in mice
- from the O2k-Network »LV Riga Makrecka-Kuka M«
- Makrecka-Kuka M, Korzh S, Videja M, Vilks K, Cirule H, Kuka J, Dambrova M, Liepinsh E (2020) Empagliflozin protects cardiac mitochondrial fatty acid metabolism in a mouse model of diet-induced lipid overload. Cardiovasc Drugs Ther [Epub ahead of print]. »Bioblast link«
- Jul-01 We
- Jul-02 Th
Did you know that if ET capacity 
is lower than OXPHOS capacity 
(P>E) in living cells or mitochondrial preparations, then you have encountered an experimental artefact? The possible triggers of this experimental artefact are:
- loss of oxidative capacity during the time course of the respirometric assay,
- insufficient uncoupler concentrations,
- over titration of an uncoupler, which inhibits ET capacity,
- inhibition of ET capacity due to the use of high oligomycin (inhibitor of the ATP synthase) concentrations employed to measure LEAK respiration prior ET capacity.Information from: Gnaiger Erich et al ― MitoEAGLE Task Group (2020) Mitochondrial physiology. Bioenerg Commun 2020.1 »Bioblast link«
- Jul-03 Fr
Mitochondrial H2O2 flux in cardiac and skeletal muscle preparations is influenced by experimental oxygen concentration
- from the O2k-Network »US CO Fort Collins Chicco AJ«
- Li Puma LC, Hedges M, Heckman JM, Mathias AB, Engstrom MR, Brown AB, Chicco AJ (2020) Experimental oxygen concentration influences rates of mitochondrial hydrogen peroxide release from cardiac and skeletal muscle preparations. Am J Physiol Regul Integr Comp Physiol 318:R972-80. »Bioblast link«
- from the O2k-Network »US CO Fort Collins Chicco AJ«
